What do stroke guidelines say about using alteplase (tPA)?
Stroke treatment guidelines consistently recommend intravenous alteplase (tPA) for eligible patients with acute ischemic stroke, most importantly when it’s given within the appropriate time window and after the patient is confirmed to have no contraindications. The decision is tightly tied to rapid imaging (to rule out hemorrhage) and clinical criteria used to estimate benefit versus risk, particularly the risk of symptomatic intracranial hemorrhage.
How fast does alteplase need to be given?
Most major stroke guidelines emphasize “as early as possible” within the recognized treatment window. Eligibility generally depends on time from symptom onset (or last-known-well) and on excluding hemorrhage on brain imaging. Practically, guidelines push systems to minimize delays in emergency evaluation, imaging, and treatment preparation.
What are the common prerequisites before giving tPA?
Guidelines typically require:
- Immediate brain imaging to rule out intracranial hemorrhage (often with CT, sometimes with additional vascular imaging depending on local protocols).
- Verification of symptom onset timing (or last-known-well time).
- Checking contraindications, especially conditions that increase the risk of bleeding.
- Basic laboratory and clinical checks as required by the guideline or local protocol (these can vary by region and agency updates).
Who is usually eligible—and who is usually excluded?
Eligibility is usually limited to patients with acute ischemic stroke who meet timing and imaging requirements and who do not have major bleeding risk factors. Patients are often excluded if imaging shows hemorrhage, if there are strong indicators of another diagnosis, or if they have specific contraindications listed in the guideline (for example, conditions that raise intracranial bleeding risk).
What about “wake-up stroke” (unknown onset) or “last-known-well”?
Some guideline pathways allow alteplase when the onset time is unknown, using advanced imaging or other criteria to identify patients most likely to benefit. These approaches depend on imaging findings and the specific guideline being followed, because the acceptable criteria and evidence thresholds differ across guideline updates.
What do guidelines say about dosing?
Guidelines specify an intravenous alteplase dosing regimen for acute ischemic stroke, including how much to give and how it is administered. Dosing is paired with strict adherence to the administration instructions used in the evidence base, since small deviations can affect safety.
What monitoring and follow-up does tPA require after administration?
Guidelines generally require close post-infusion monitoring for neurologic change and for complications, with repeat assessment for any signs of intracranial bleeding. Blood pressure control and serial neurologic checks are common elements of the recommended post-tPA care pathway.
If alteplase isn’t an option, what do guidelines recommend instead?
When alteplase is contraindicated or outside the recommended time window, guidelines usually pivot to other evidence-based care for acute ischemic stroke, which may include mechanical thrombectomy for patients with large-vessel occlusion who meet imaging and clinical criteria, plus standard stroke-unit supportive management.
Where can I confirm the exact guideline text?
If you want the precise wording and criteria (time windows, contraindications, and dosing), you’ll typically need to use a specific guideline document (e.g., national stroke society guidance or an international guideline update). If you tell me your country/region (US, UK, Canada, EU, etc.) and whether you mean adult or pediatric stroke, I can point you to the most relevant guideline version and key decision points.
Sources
No sources were provided with your prompt, so I can’t cite specific guideline documents directly yet.